ARCHIVES

Anticancer Vaccine Trials Due In Three-Four Years; Virus Research Opportunities Described

This article is from The Cancer Letter archive.

Vol. 01 No. 30 | July 25, 1975

Download PDF Visit The Full Archive

Related Articles

Simone Replaces Levine As Cancer Policy Board Chairman

April 19, 2002

FDA Approves Inlyta Pill For Renal Cell Carcinoma

January 27, 2012

NCI RFA Available: Minority-Based CCOPS

August 15, 1997

Advisors Clear Herceptin; Find Tamoxifen Indicated For “Short Term Risk Reduction”

September 11, 1998

In Brief: PCORI Forms Clinical Trials Advisory Board

April 4, 2014

In Brief: New NCAB Members Briefed At Orientation Wogan Resigns From Board; Parry Names NCCP Deputy

September 10, 1982